Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment
MT Newswires Live
Oct 21
Neurizon Therapeutics (ASX:NUZ) was told by the Australian Patent Office of the grant of a new method of use patent, which will extend protection for its NUZ-001 drug candidate and related compounds across key therapeutic areas, including mTOR-pathway related diseases, such as amyotrophic lateral sclerosis, and other neurodegenerative diseases, according to a Tuesday Australian bourse filing.
The granted patent complements Neurizon's existing US patent for NUZ-001 in neurodegenerative diseases and cancer and gives the firm unified intellectual property protection through to May 2041 across major global markets, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.